Autologous Th2-polarized lymphocytes induce atopic dermatitis lesions in non-atopic human skin xenotransplants.
IL-2
IL-4
LPS
SCID mice
perceived stress
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
24
09
2022
received:
14
03
2022
accepted:
14
10
2022
medline:
2
6
2023
pubmed:
5
1
2023
entrez:
4
1
2023
Statut:
ppublish
Résumé
The key signals that suffice to induce atopic dermatitis (AD) in human skin remain incompletely understood. Also, current mouse models reflect human AD only unsatisfactorily. Therefore, we have asked whether a humanized AD mouse model can be developed that reflects human AD more faithfully and permit to identify key signals that suffice to induce AD lesions in previously healthy human skin in vivo. Healthy human skin from non-atopic donors was transplanted onto SCID/beige mice. After xenotransplant reinnervation by mouse sensory nerve fibers had occurred, mixed autologous human Th2 CD4+ and Tc2 CD8+ T cells that had been pretreated in vitro with IL-2, IL-4, and LPS were injected intradermally into the xenotransplants without skin barrier disruption. Injected non-atopic xenotransplants rapidly developed a morphological, functional, and immunological phenocopy of human AD lesions regarding skin barrier defects, immunopathology including intraepidermal eosinophils, mast cell activation, increase of thymic stromal lymphopoietin, eotaxin-1 and type 2 cytokine circuits, and even showed characteristic neuroimmunological abnormalities such as ß2-adrenergic receptor downregulation. The experimentally induced AD lesions in human skin responded to standard AD therapy (topical dexamethasone or tacrolimus; systemic anti-IL-4Rα antibody [dupilumab]), and relapsed when neurogenic skin inflammation was induced by exposing mice to perceived stress. This new animal model uniquely mimics the complexity of human AD and its clinical response to standard therapy and psychoemotional stressors in vivo, and shows that Th2-polarized lymphocytes associated with excessive IL-4Rα-mediated signaling suffice to induce human AD skin lesions, while atopy and epidermal barrier disruption are dispensable.
Sections du résumé
BACKGROUND
The key signals that suffice to induce atopic dermatitis (AD) in human skin remain incompletely understood. Also, current mouse models reflect human AD only unsatisfactorily. Therefore, we have asked whether a humanized AD mouse model can be developed that reflects human AD more faithfully and permit to identify key signals that suffice to induce AD lesions in previously healthy human skin in vivo.
METHODS
Healthy human skin from non-atopic donors was transplanted onto SCID/beige mice. After xenotransplant reinnervation by mouse sensory nerve fibers had occurred, mixed autologous human Th2 CD4+ and Tc2 CD8+ T cells that had been pretreated in vitro with IL-2, IL-4, and LPS were injected intradermally into the xenotransplants without skin barrier disruption.
RESULTS
Injected non-atopic xenotransplants rapidly developed a morphological, functional, and immunological phenocopy of human AD lesions regarding skin barrier defects, immunopathology including intraepidermal eosinophils, mast cell activation, increase of thymic stromal lymphopoietin, eotaxin-1 and type 2 cytokine circuits, and even showed characteristic neuroimmunological abnormalities such as ß2-adrenergic receptor downregulation. The experimentally induced AD lesions in human skin responded to standard AD therapy (topical dexamethasone or tacrolimus; systemic anti-IL-4Rα antibody [dupilumab]), and relapsed when neurogenic skin inflammation was induced by exposing mice to perceived stress.
CONCLUSIONS
This new animal model uniquely mimics the complexity of human AD and its clinical response to standard therapy and psychoemotional stressors in vivo, and shows that Th2-polarized lymphocytes associated with excessive IL-4Rα-mediated signaling suffice to induce human AD skin lesions, while atopy and epidermal barrier disruption are dispensable.
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1538-1553Informations de copyright
© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Nomura T, Wu J, Kabashima K, Guttman-Yassky E. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J Allergy Clin Immunol Pract. 2020;8(6):1840-1852.
Luger T, Amagai M, Dreno B, et al. Atopic dermatitis: role of the skin barrier, environment, microbiome, and therapeutic agents. J Dermatol Sci. 2021;102(3):142-157.
Honda T, Kabashima K. Reconciling innate and acquired immunity in atopic dermatitis. J Allergy Clin Immunol. 2020;145(4):1136-1137.
Gilhar A, Reich K, Keren A, Kabashima K, Steinhoff M, Paus R. Mouse models of atopic dermatitis: a critical reappraisal. Exp Dermatol. 2021;30(3):319-336.
Barilla S, Felix K, Jorizzo JL. Stressors in atopic dermatitis. Adv Exp Med Biol. 2017;1027:71-77.
Shen Q, Zhang Q, Zhao J, et al. Association between maternal perceived stress in all trimesters of pregnancy and infant atopic dermatitis: a prospective birth cohort study. Front Pediatr. 2020;8:526994.
Hedman-Lagerlöf E, Fust J, Axelsson E, et al. Internet-delivered cognitive behavior therapy for atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(7):796-804.
Mochizuki H, Schut C, Nattkemper LA, Yosipovitch G. Brain mechanism of itch in atopic dermatitis and its possible alteration through non-invasive treatments. Allergol Int. 2017;66(1):14-21.
Ersser SJ, Cowdell F, Latter S, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2014;2014(1):CD004054.
Loyal L, Warth S, Jürchott K, et al. SLAMF7 and IL-6R define distinct cytotoxic versus helper memory CD8 + T cells. Nat Commun. 2020;11(1):6357.
Nakajima S, Nomura T, Common J, Kabashima K. Insights into atopic dermatitis gained from genetically defined mouse models. J Allergy Clin Immunol. 2019;143(1):13-25.
Röcken M, Schallreuter K, Renz H, Szentivanyi A. What exactly is “atopy”? Exp Dermatol. 1998;7(2-3):97-104.
Keren A, Shemer A, Ginzburg A, et al. Innate lymphoid cells 3 induce psoriasis in xenotransplanted healthy human skin. J Allergy Clin Immunol. 2018;142(1):305-308.e6.
de Oliveira VL, Keijsers RR, van de Kerkhof PC, et al. Humanized mouse model of skin inflammation is characterized by disturbed keratinocyte differentiation and influx of IL-17A producing T cells. PLoS One. 2012;7(10):e45509.
Soria A, Boccara D, Chonco L, et al. Long-term maintenance of skin immune system in a NOD-Scid IL2rγ(null) mouse model transplanted with human skin. Exp Dermatol. 2014;23(11):850-852.
Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015;75(1):68-78.
Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 2007;8(12):1142-1148.
Ross SH, Cantrell DA. Signaling and function of Interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36:411-433.
Palmqvist N, Siller M, Klint C, Sjödin A. A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030. J Inflamm (Lond). 2016;13:20.
Gu Y, Li K, Sun J, Zhang J. Characterization of CD19+ CD24hi CD38hi B cells in Chinese adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(12):2863-2870.
Lee HN, Shin SA, Choo GS, et al. Anti-inflammatory effect of quercetin and galangin in LPS-stimulated RAW264.7 macrophages and DNCB-induced atopic dermatitis animal models. Int J Mol Med. 2018;41(2):888-898.
Reddel S, Del Chierico F, Quagliariello A, et al. Gut microbiota profile in children affected by atopic dermatitis and evaluation of intestinal persistence of a probiotic mixture. Sci Rep. 2019;9(1):4996.
Ovsiy I, Riabov V, Manousaridis I, et al. IL-4 driven transcription factor FoxQ1 is expressed by monocytes in atopic dermatitis and stimulates monocyte migration. Sci Rep. 2017;7:16847.
Höper T, Siewert K, Dumit VI, von Bergen M, Schubert K, Haase A. The contact allergen NiSO4 triggers a distinct molecular response in primary human dendritic cells compared to bacterial LPS. Front Immunol. 2021;12:644700.
Gu H, Zhu Y, Jia T, Li X, Lu Y, Kaku K. Development of a new eczema-like reconstructed skin equivalent for testing child atopic dermatitis-relieving cosmetics. J Cosmet Dermatol. 2020;19(3):752-757.
Riethmuller C, McAleer MA, Koppes SA, et al. Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis. J Allergy Clin Immunol. 2015;136(6):1573-1580.
Arck PC, Handjiski B, Hagen E, Joachim R, Klapp BF, Paus R. Indications for a ‘brain-hair follicle axis (BHA)’: inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P. FASEB J. 2001;15(13):2536-2538.
Arck PC, Handjiski B, Kuhlmei A, et al. Mast cell deficient and neurokinin-1 receptor knockout mice are protected from stress-induced hair growth inhibition. J Mol Med (Berl). 2005;83(5):386-396.
Joachim RA, Kuhlmei A, Dinh QT, et al. Neuronal plasticity of the “brain-skin connection”: stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factor-dependent pathways. J Mol Med (Berl). 2007;85(12):1369-1378.
Peters EM, Handjiski B, Kuhlmei A, et al. Neurogenic inflammation in stress-induced termination of murine hair growth is promoted by nerve growth factor. Am J Pathol. 2004;165(1):259-271.
Gherardini J, van Lessen M, Piccini I, Edelkamp J, Bertolini M. Human wound healing ex vivo model with focus on molecular markers. Methods Mol Biol. 2020;2154:249-254.
Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155-172.
Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis-a review on behalf of the international eczema council. J Allergy Clin Immunol. 2021;147(4):1174-1190.
Harries MJ, Meyer K, Chaudhry I, et al. Lichen planopilaris is characterized by immune privilege collapse of the hair follicle's epithelial stem cell niche. J Pathol. 2013;231(2):236-247.
Bertolini M, Zilio F, Rossi A, et al. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS One. 2014;9(5):e94260.
Furue M, Ulzii YH, Vu G, et al. Atopic dermatitis and type 2 immune deviation. Curr Treat Options Allergy. 2019;6:200-210.
O'Garra A, Gabryšová L. Transcription factors directing Th2 differentiation: Gata-3 plays a dominant role. J Immunol. 2016;196(11):4423-4425.
Alkon N, Bauer WM, Krausgruber T, et al. Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis. J Allergy Clin Immunol. 2022;149(2):624-639.
Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Targeting IL-4 for the treatment of atopic dermatitis. Immunotargets Ther. 2020;9:151-156.
Nakajima S, Tie D, Nomura T, Kabashima K. Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans. Cytokine. 2021;148:155664.
He H, Bissonnette R, Wu J, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021;147(1):199-212.
Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160.
Lessard JC, Piña-Paz S, Rotty JD, et al. Keratin 16 regulates innate immunity in response to epidermal barrier breach. Proc Natl Acad Sci USA. 2013;110(48):19537-19542.
Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603-613.
Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126:21-31.
Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int J Mol Sci. 2020;21(8):2867.
Bergmann S, von Buenau B, Vidal-Y-Sy S, et al. Claudin-1 decrease impacts epidermal barrier function in atopic dermatitis lesions dose-dependently. Sci Rep. 2020;10(1):2024.
Nomura T, Honda T, Kabashima K. Multipolarity of cytokine axes in the pathogenesis of atopic dermatitis in terms of age, race, species, disease stage and biomarkers. Int Immunol. 2018;30(9):419-428.
Pavel AB, Renert-Yuval Y, Wu J, et al. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy. 2021;76(1):314-325.
Riethmüller C. Assessing the skin barrier via corneocyte morphometry. Exp Dermatol. 2018;27(8):923-930.
Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324-336.
Smieszek SP, Welsh S, Xiao C, et al. Correlation of age-of-onset of atopic dermatitis with Filaggrin loss-of-function variant status. Sci Rep. 2020;10(1):2721.
Clausen ML, Kezic S, Olesen CM, Agner T. Cytokine concentration across the stratum corneum in atopic dermatitis and healthy controls. Sci Rep. 2020;10(1):21895.
Adhikary PP, Tan Z, Page BDG, Hedtrich S. TSLP as druggable target - a silver-lining for atopic diseases? Pharmacol Ther. 2021;217:107648.
Kuwatsuka Y, Murota H. Involvement of Periostin in skin function and the pathogenesis of skin diseases. Adv Exp Med Biol. 2019;1132:89-98.
Furue M, Ulzii D, Vu YH, Tsuji G, Kido-Nakahara M, Nakahara T. Pathogenesis of atopic dermatitis: current paradigm. Iran J Immunol. 2019;16(2):97-107.
Otsuka A, Nomura T, Rerknimitr P, Seidel JA, Honda T, Kabashima K. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunol Rev. 2017;278(1):246-262.
Valdebran M, Kowalski EH, Kneiber D, et al. Epidermal expression of eotaxins and thymic stromal lymphopoietin in eosinophil rich dermatoses. Arch Dermatol Res. 2019;311(9):705-710.
Ahn J, Choi Y, Simpson EL. Therapeutic new era for atopic dermatitis: part 1. Biologics. Ann Dermatol. 2021;33(1):1-10.
Yang X, Kambe N, Takimoto-Ito R, Kabashima K. Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. Pharmacol Ther. 2021;224:107830.
Herrmann N, Nümm TJ, Iwamoto K, et al. Vitamin D3-induced promotor dissociation of PU.1 and YY1 results in FcεRI reduction on dendritic cells in atopic dermatitis. J Immunol. 2021;206(3):531-539.
Gomez G. Current strategies to inhibit high affinity FcεRI-mediated signaling for the treatment of allergic disease. Front Immunol. 2019;10:175.
Schallreuter KU, Wei Y, Pittelkow MR, Swanson NN, Gibbons NC, Wood JM. Structural and functional alterations in the beta2-adrenoceptor are caused by a point mutation in patients with atopic eczema. Exp Dermatol. 2007;16(10):807-813.
Oetjen LK, Kim BS. Interactions of the immune and sensory nervous systems in atopy. FEBS J. 2018;285(17):3138-3151.
Choi JE, Di Nardo A. Skin neurogenic inflammation. Semin Immunopathol. 2018;40(3):249-259.
Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol. 2000;114(6):1108-1112.
Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the ‘brain-skin connection’. Trends Immunol. 2006;27(1):32-39.
Cevikbas F, Lerner EA. Physiology and pathophysiology of itch. Physiol Rev. 2020;100(3):945-982.
Siiskonen H, Harvima I. Mast cells and sensory nerves contribute to neurogenic inflammation and pruritus in chronic skin inflammation. Front Cell Neurosci. 2019;13:422.
Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136-1143.
Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91-101.
Grigore O, Mihailescu AI, Solomon I, Boda D, Caruntu C. Role of stress in modulation of skin neurogenic inflammation. Exp Ther Med. 2019;17(2):997-1003.
Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(2):239-250.
Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. 2006;126(8):1697-1704.
Hunter HJ, Momen SE, Kleyn CE. The impact of psychosocial stress on healthy skin. Clin Exp Dermatol. 2015;40(5):540-546.
Sun MD, Rieder EA. Psychosocial stress and mechanisms of skin health: a comprehensive update. J Drugs Dermatol. 2021;20(1):62-69.
Ertle CM, Rommel FR, Tumala S, et al. New pathways for the Skin's stress response: the cholinergic neuropeptide SLURP-1 can activate mast cells and Alter cytokine production in mice. Front Immunol. 2021;12:631881.
Lu Z, Hasse S, Bodo E, Rose C, Funk W, Paus R. Towards the development of a simplified long-term organ culture method for human scalp skin and its appendages under serum-free conditions. Exp Dermatol. 2007;16(1):37-44.
Gherardini J, Uchida Y, Hardman JA, et al. Tissue-resident macrophages can be generated de novo in adult human skin from resident progenitor cells during substance P-mediated neurogenic inflammation ex vivo. PLoS One. 2020;15(1):e0227817.
Chéret J, Gherardini J, Soeberdt M, et al. Non-neuronal kappa-opioid receptor activation enhances epidermal keratinocyte proliferation, and modulates mast cell functions in human skin ex vivo. J Dermatol. 2020;47(8):917-921.
Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21-40.
Karo-Atar D, Bitton A, Benhar I, Munitz A. Therapeutic targeting of the Interleukin-4/Interleukin-13 signaling pathway: in allergy and beyond. BioDrugs. 2018;32(3):201-220.
Tatsuno K, Fujiyama T, Yamaguchi H, Waki M, Tokura Y. TSLP directly interacts with skin-homing Th2 cells highly expressing its receptor to enhance IL-4 production in atopic dermatitis. J Invest Dermatol. 2015;135(12):3017-3024.
Kortekaas Krohn I, Aerts JL, Breckpot K, et al. T-cell subsets in the skin and their role in inflammatory skin disorders. Allergy. 2022;77(3):827-842.
Czarnowicki T, Santamaria-Babí LF, Guttman-Yassky E. Circulating CLA+ T cells in atopic dermatitis and their possible role as peripheral biomarkers. Allergy. 2017;72(3):366-372.
Meštrović-Štefekov J, Novak-Bilić G, Kuna M, Pap N, Lugović-Mihić L. Psychological stress in patients with atopic dermatitis. Acta Dermatovenerol Croat. 2018;26(4):297-303.
Suárez AL, Feramisco JD, Koo J, Steinhoff M. Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates. Acta Derm Venereol. 2012;92(1):7-15.
Morren MA, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H. Atopic dermatitis: triggering factors. J Am Acad Dermatol. 1994;31(3 Pt 1):467-473.
Meng J, Li Y, Fischer MJM, Steinhoff M, Chen W, Wang J. Th2 modulation of transient receptor potential channels: an unmet therapeutic intervention for atopic dermatitis. Front Immunol. 2021;12:696784.
Moniaga CS, Tominaga M, Takamori K. The pathology of type 2 inflammation-associated itch in atopic dermatitis. Diagnostics (Basel). 2021;11(11):2090.
Tsoi LC, Rodriguez E, Stölzl D, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J Allergy Clin Immunol. 2020;145(5):1406-1415.
Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354.
Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2021;21:1-20.
Bangert C, Rindler K, Krausgruber T, et al. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Rα blockade. Sci Immunol. 2021;6(55):eabe2749.
Czarnowicki T, Gonzalez J, Shemer A, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol. 2015;136(1):104-115.e7.
Bakker DS, Nierkens S, Knol EF, et al. Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. J Allergy Clin Immunol. 2021;147(1):189-198.
Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65-S76.
Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Exp Dermatol. 2018;27(4):409-417.
Zhang C, Chinnappan M, Prestwood CA, et al. Interleukins 4 and 13 drive lipid abnormalities in skin cells through regulation of sex steroid hormone synthesis. Proc Natl Acad Sci USA. 2021;118(38):e2100749118.
Margolis DJ, Mitra N, Berna R, et al. Associating filaggrin copy number variation and atopic dermatitis in African-Americans: challenges and opportunities. J Dermatol Sci. 2020;98(1):58-60.
Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446.
Teye K, Numata S, Krol RP, et al. Prevalence of filaggrin gene mutations in patients with atopic dermatitis and ichthyosis vulgaris in Kyushu area of Japan and South Korea. J Dermatol Sci. 2017;86(2):174-177.
Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40:84-92.
Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(5):449-455.